Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.

Teixeira AL, Gomes M, Nogueira A, Azevedo AS, Assis J, Dias F, Santos JI, Lobo F, Morais A, Maurício J, Medeiros R.

PLoS One. 2013 Aug 9;8(8):e72419. doi: 10.1371/journal.pone.0072419. eCollection 2013. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/47bdb3be-4110-48de-a29d-e4734e64f6a0.

2.

Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.

Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA.

Cancer Res. 2008 Jun 15;68(12):4709-18. doi: 10.1158/0008-5472.CAN-07-6289.

3.

Stromal TGF-β signaling induces AR activation in prostate cancer.

Yang F, Chen Y, Shen T, Guo D, Dakhova O, Ittmann MM, Creighton CJ, Zhang Y, Dang TD, Rowley DR.

Oncotarget. 2014 Nov 15;5(21):10854-69.

4.

TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population.

Jin G, Deng Y, Miao R, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Wang L, Chen W, Shen J, Wang X, Xu Y, Shen H.

J Cancer Res Clin Oncol. 2008 Mar;134(3):345-51. Epub 2007 Aug 7.

PMID:
17680270
5.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

6.

The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration.

Fraga A, Ribeiro R, Príncipe P, Lobato C, Pina F, Maurício J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R.

Eur J Cancer. 2014 Jan;50(2):359-65. doi: 10.1016/j.ejca.2013.09.001. Epub 2013 Sep 30.

PMID:
24090974
7.

Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.

Fujimoto N, Kubo T, Inatomi H, Bui HT, Shiota M, Sho T, Matsumoto T.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):336-40. doi: 10.1038/pcan.2013.23. Epub 2013 Jul 30.

PMID:
23896625
8.

Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.

Wagner J, Damaschke N, Yang B, Truong M, Guenther C, McCormick J, Huang W, Jarrard D.

PLoS One. 2015 Apr 15;10(4):e0124366. doi: 10.1371/journal.pone.0124366. eCollection 2015.

9.

TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.

Busch S, Acar A, Magnusson Y, Gregersson P, Rydén L, Landberg G.

Oncogene. 2015 Jan 2;34(1):27-38. doi: 10.1038/onc.2013.527. Epub 2013 Dec 16.

PMID:
24336330
10.

[Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer].

Zhou Y, Jin GF, Jiang GJ, Wang HM, Tan YF, Ding WL, Wang LN, Chen WS, Ke Q, Shen J, Xu YC, Shen HB.

Ai Zheng. 2007 Jun;26(6):581-5. Chinese.

PMID:
17562261
11.

Polymorphisms of TGFβ-1 and TGFBR2 in relation to coronary artery disease in a Chinese population.

Yang M, Zhu M, Tang L, Zhu H, Lu Y, Xu B, Jiang J, Chen X.

Clin Biochem. 2016 Aug;49(12):873-8. doi: 10.1016/j.clinbiochem.2016.05.022. Epub 2016 May 24.

PMID:
27234600
12.

Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer.

Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, Huang T, Sun LZ.

Oncogene. 2014 Jul 31;33(31):4097-106. doi: 10.1038/onc.2013.374. Epub 2013 Sep 16.

13.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
14.

Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma.

Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Shan B.

Mol Biol Rep. 2012 Oct;39(10):9453-62. doi: 10.1007/s11033-012-1810-x. Epub 2012 Jun 22.

PMID:
22722999
15.

Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.

Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G.

Urol Oncol. 2014 May;32(4):426-32. doi: 10.1016/j.urolonc.2013.09.006. Epub 2013 Dec 12.

PMID:
24332637
16.

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS.

J Clin Oncol. 2010 Jun 1;28(16):2668-73. doi: 10.1200/JCO.2009.25.1330. Epub 2010 Apr 26.

17.

A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.

Shibahara T, Onishi T, Franco OE, Arima K, Nishikawa K, Yanagawa M, Hioki T, Watanabe M, Hirokawa Y, Shiraishi T, Sugimura Y.

Anticancer Res. 2006 Sep-Oct;26(5A):3365-71.

18.

Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.

Teixeira AL, Ribeiro R, Cardoso D, Pinto D, Lobo F, Fraga A, Pina F, Calais-da-Silva F, Medeiros R.

Clin Cancer Res. 2008 Jun 1;14(11):3367-71. doi: 10.1158/1078-0432.CCR-07-5119.

20.

Anti-Androgenic Activity of Icarisid II from Epimedium Herb in Prostate Cancer LNCaP Cells.

Miura Y, Oyama M, Iguchi K, Ito T, Baba M, Shikama Y, Usui S, Hirano K, Iinuma M, Mikamo H.

J Nutr Sci Vitaminol (Tokyo). 2015;61(2):201-4. doi: 10.3177/jnsv.61.201.

Supplemental Content

Support Center